Fresenius Kabi recalls anti-inflammation drug Ketorolac after finding particles in vials
Fresenius Kabi was recently knocked by the Chinese government for lots of BeiGene-imported Abraxane. (Fresenius Kabi)
German drugmaker Fresenius Kabi has made major investments in its U.S. manufacturing operations in recent years with some mixed quality results along the way. Now, one of the drugmaker's products faces a recall for more manufacturing woes.
Fresenius Kabi has recalled 13 lots of Ketorolac Tromethamine Injection after carbon, silicon, oxygen and polyamide particulates were found in eight vials of the anti-inflammation drug, the FDA said in an April 20 posting.
The recall covers 30- and 60-milligram doses of the drug distributed between May 5, 2018 and Dec. 16, the FDA said.
Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes
Wednesday, March 24 | 2pm ET / 11am PT
Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.
Fresenius has notified its distributor and customers of the recall and advised them "to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product."